Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report.
Crit Rev Oncol Hematol
; 39(1-2): 17-23, 2001.
Article
in En
| MEDLINE
| ID: mdl-11418298
ABSTRACT
We report the successful treatment of a patient with recurrent malignant glioma with adoptive cellular immunotherapy. The patient is a young adult with recurrent progressive disease refractory to aggressive multi-modality therapy including repetitive surgical resection, radiation, radiosurgery and chemotherapy. He received multiple courses of local administration of autologous lymphokine-activated killer (LAK) cells in combination with a low dose of interleukin-2 (IL-2) through an Ommaya reservoir-catheter system. The side-effects of this treatment were limited and manageable. The patient achieved a complete remission, as demonstrated by MRI and confirmed by glucose-positron emission tomography (PET) imaging 11 months after initiation of immune therapy. Twenty-six months later, the patient is still in remission with improving performance status. Adoptive cellular immunotherapy utilizing autologous LAK cells with low dose IL-2 appears to be a safe and effective therapy for a subset of patients with primary, recurrent or progressive malignant glioma following conventional therapy.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunotherapy, Adoptive
/
Glioma
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
Crit Rev Oncol Hematol
Year:
2001
Document type:
Article